{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:34:30Z","timestamp":1786545270717,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/ajg.2012.224","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T06:01:44Z","timestamp":1346911304000},"page":"1423-1425","source":"Crossref","is-referenced-by-count":1,"title":["Editorial: What to Take From TREAT?"],"prefix":"10.14309","volume":"107","author":[{"given":"Stephen B","family":"Hanauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20210210","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. Crohns Disease cA2 Study Group.","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"R2-25-20210210","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.gtc.2006.09.006","article-title":"Infusion reactions and their management.","volume":"35","author":"Mayer","year":"2006","journal-title":"Gastroenterol Clin North Am"},{"key":"R3-25-20210210","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohns disease.","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"R4-25-20210210","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"R5-25-20210210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohns disease: the Mayo clinic experience in 500 patients.","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"R7-25-20210210","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohns disease.","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"R8-25-20210210","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohns disease: a meta-analysis.","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-25-20210210","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1046\/j.1365-2036.2001.01060.x","article-title":"Review article: the limitations of corticosteroid therapy in Crohns disease.","volume":"15","author":"Rutgeerts","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-25-20210210","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MAJ.0b013e31821ff728","article-title":"Viral infections in patients with inflammatory bowel disease on immunosuppressants.","volume":"343","author":"Ali","year":"2012","journal-title":"Am J Med Sci"},{"key":"R11-25-20210210","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"R15-25-20210210","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease.","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"R16-25-20210210","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohns disease.","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R17-25-20210210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohns disease: TREAT registry.","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R18-25-20210210","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"R19-25-20210210","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease.","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"R20-25-20210210","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","article-title":"The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.","volume":"68","author":"Leombruno","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R21-25-20210210","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohns disease.","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"R22-25-20210210","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R23-25-20210210","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in IBD.","volume":"106","author":"Yanai","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R24-25-20210210","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"R25-25-20210210","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R26-25-20210210","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohns disease.","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"R27-25-20210210","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohns disease.","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R28-25-20210210","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohns disease treated with scheduled infliximab maintenance: a randomized trial.","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"R29-25-20210210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gut.2010.236869","article-title":"Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment.","volume":"61","author":"Vande Casteele","year":"2012","journal-title":"Gut"},{"key":"R30-25-20210210","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ibd.21259","article-title":"Monitoring functional serum antitumor necrosis factor antibody level in Crohns disease patients who maintained and those who lost response to anti-TNF.","volume":"16","author":"Yamada","year":"2010","journal-title":"Inflamm Bowel Dis"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2012224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2012224","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2012224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201209000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:38:58Z","timestamp":1786541938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201209000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2012.224","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}